

Acta Med. Okayama, 2013
Vol. 67, No. 4, pp. 265-269

Copyright©2013 by Okayama University Medical School.

Acta Medica
Okayama

<http://escholarship.lib.okayama-u.ac.jp/amo/>

Case Report

Large Ulceration of the Oropharynx Induced by Methotrexate-Associated Lymphoproliferative Disorders

Hiroyuki Hanakawa^a, Yori-hisa Orita^{a*}, Yasuharu Sato^b, Kinya Uno^c,
Kazunori Nishizaki^a, and Tadashi Yoshino^b

Departments of ^aOtolaryngology Head and Neck Surgery, ^bPathology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan, ^cUno-kin ENT hospital, Okayama 700-0985, Japan

We present a case of a 67-year-old Japanese man with a serious oropharyngeal ulceration that at first seemed to be destructive malignant lymphoma or oropharyngeal carcinoma. We suspected methotrexate (MTX)-associated lymphoproliferative disorder (LPD) induced by MTX treatment for rheumatoid arthritis (RA). About 3 weeks after simple discontinuation of MTX, complete regression of the disease was observed, confirming our diagnosis.

Key words: ulceration, methotrexate, oropharynx, lymphoproliferative disorders

O ral ulceration can occur as a side effect of methotrexate (MTX) therapy, which may often be due to a lack of folic acid supplementation or an overdosage of the drug [1]. Adverse effects, which are experienced by up to 80% of patients on long-term, low-dose MTX therapy, may develop at any stage of treatment, even after 30 years [2-4]. These effects are usually mild and well tolerated, and are relatively easily reversed by folate administration and either reduction or discontinuation of the drug [5]. Iatrogenic lymphoproliferative disorders (LPD) are atypical lymphoid proliferations or lymphomas that arise in patients treated with immunosuppressive drugs such as MTX [6]. Although some case reports have described the spontaneous regression and disappearance of lymphoproliferative lesions after simple discontinuation of MTX [7, 8], MTX-associated LPDs in rheumatoid arthritis (RA) patients could be crucial and sometimes need aggressive treatment,

including chemotherapy and/or radiation therapy [7, 9]. Hence, it is important to determine whether or not MTX-associated adverse events are reversible. The present case report describes an RA patient with a seemingly critical oropharyngeal ulceration that was probably induced by MTX therapy and that indeed resolved immediately after MTX withdrawal.

Case Report

Clinical history. A 67-year-old Japanese man was referred to our department for evaluation of a large and deep ulceration over the right oropharynx, which limited his ability to open his mouth (Fig. 1). The ulceration looked as if a right tonsillectomy had been performed. Although he had been experiencing pharyngeal pain for 6 months, the pain had recently worsened enough to cause difficulty in ingestion and a tendency toward dehydration. The rest of the physical examination of the head and neck region was unremarkable. There was no ulceration other than at the right oropharynx. Full-body computed tomography revealed only the ulceration over the right orophar-

Received October 18, 2012; accepted February 5, 2013.

*Corresponding author. Phone: +81-86-235-7307; Fax: +81-86-235-7308
E-mail: y.orita@live.jp (Y. Orita)




Fig. 1 A large and deep ulceration over the right oropharynx limited mouth opening.

ynx, and no other abnormalities such as lymphadenopathy.

The patient's medical history revealed that he had suffered from RA for 23 years and was currently being treated with MTX, prednisolone, sodium aurothiomalate, and diclofenac sodium. He had been treated for over 20 years with a 6mg/week dose of MTX (oral administration) and 25mg/2 weeks of sodium aurothiomalate (intravenous injection), and his disease had been controlled mainly by altering the dose of oral prednisolone (0–10mg/day). The pain had been controlled by diclofenac sodium (oral administration) with a maximum dose of 75mg/day. There was no other medication than these 4 kinds of drugs. Since his RA had progressively worsened, the dosage of MTX had been gradually increased to a once-weekly dose of 12mg/2 weeks during the 10 months prior to his current history and presentation; administration of sodium aurothiomalate had been discontinued 10 months earlier. Our first clinical impression was destructive malignant lymphoma or carcinoma of the oropharynx. We also considered the possibility of MTX therapy as a causative even though we did not consider the dose of MTX to be very high.

To make a definitive diagnosis, a biopsy of the ulcer was performed. The biopsy samples demonstrated an ulcer with granulation tissue, and severe inflammatory cell infiltration was found in the submucosa (Fig. 2A). A high-power view revealed polymorphic features in the lesion, namely, numerous large atypical lymphoid cell proliferations with small lymphocytes (Fig. 2B). On immunohistochemical study, the large atypical lymphoid cells were positive for CD20, CD79a, and CD30, and negative for CD3

(Fig. 2C). These cells were also positive for Epstein-Barr virus-encoded small RNA oligonucleotides (Fig. 2D). Thus, a diagnosis of MTX-associated LPD was made.

In laboratory findings, the white blood cell count was 8,310/ μ l; C-reactive protein, 5.64mg/dl (reference range, <0.30mg/dl); lactate dehydrogenase, 215IU/l (120–240IU/l); and soluble interleukin-2 receptor, 666 U/ml (122–496 U/ml).

The patient was admitted to our hospital to receive intravenous nourishment. He was advised not to take any more MTX, and was started on the intravenous administration of 10mg prednisolone/day. Cessation of MTX gave him immediate relief from the pharyngeal pain. Surprisingly, a review after 3 weeks demonstrated almost complete resolution of the ulcer and abatement of his symptoms (Fig. 3). Our histological diagnosis of MTX-associated LPD was thus confirmed by the clinical outcome. The patient is now treated with prednisolone and tacrolimus hydrate, and his RA remains well controlled.

Discussion

Since MTX mostly affects cells undergoing rapid turnover, including mucosal and bone marrow cells, myelosuppression and mucositis are among the more commonly reported adverse reactions to MTX [10]. Oral ulceration is experienced by 14% of patients on long-term, low-dose MTX therapy, and established lesions are exacerbated by further administration of the drug but heal within about 3 weeks after MTX discontinuation [11]. This side effect of MTX is generally dose-dependent and often occurs due to an




Fig. 2 The biopsy samples demonstrated an ulcer with granulation tissue, and severe inflammatory cell infiltration was seen in the submucosa (A) (Hematoxylin and eosin staining). A high-power view revealed polymorphic features of the lesion, namely, the proliferation of numerous large atypical lymphoid cells with small lymphocytes (B) (Hematoxylin and eosin staining). On immunohistochemistry, large atypical lymphoid cells were positive for CD20 (C), CD79a, and CD30, and were negative for CD3. Moreover, large atypical lymphoid cells were positive for Epstein-Barr virus-encoded small RNA oligonucleotides (D).



Fig. 3 Three weeks after the cessation of MTX, almost complete resolution of the ulcer was observed. Now the patient can open his mouth fully.

accidental overdosage of MTX [12]. MTX is usually given in a once-weekly dose of up to 25 mg [13]. Hence, it was not likely that the side effect seen in our patient was due to overdosage of MTX, because the maximum dosage in the present case was only 12 mg/

week. Oral side effects are of significance to the patient not only because of the pain but also as a factor affecting diet, exacerbating folate deficiency, causing weight loss, and leading to a general deterioration of health [14]. It has been reported that folic acid supplementation can result in a 79% reduction in mucosal and gastrointestinal side effects of MTX [15]. Aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) can reduce MTX excretion by their effect on renal tubules. Hence, the British national formulary advises that the MTX dose should be carefully monitored in patients concurrently receiving aspirin or other NSAIDs [12]. When RA and oral ulceration worsen, patients may be inclined to increase their NSAID dosage, which might result in a vicious cycle that includes worsening of the oral ulceration. Our patient was also treated with diclofenac sodium, but the maximum dose was 75 mg/day. Although sodium aurothiomalate may also induce oral ulcers [16], administration of this drug in the present case was stopped at least 4 months prior before the symptom of pharyngeal pain first occurred.

Adverse events with MTX are usually mild and well tolerated [5]. To our knowledge, the ulceration of

the oropharynx in the present case seems to be the most advanced one associated with MTX therapy that has ever been reported. Thus, we considered that this ulceration was the LPD lesion itself, not the advanced stage of oral ulceration or LPD combined with oral ulceration, although it may be difficult to show evidence to back up this assertion. The frequency of extranodal occurrence of MTX-induced LPD is about 40% [17]. Since RA disease activity correlates with higher rates of malignant lymphoma and LPD [18], the possibility of iatrogenic LPD or malignant lymphoma was suspected in the present case. In MTX-associated LPD patients, the mean duration of MTX treatment was 5.2 years (range, 1.4–13 years) with a mean cumulative dose of 2,200 mg (range 500–5,200 mg) [19]. In the present case, the duration of treatment was about 20 years and the total dose of MTX was about 3,800 mg. Although it has been reported that there was no relationship between the total dose of MTX or the duration of MTX treatment and the occurrence of LPD in RA patients [17, 20, 21], the extremely long period of MTX treatment in the present case might be related to such a severe LPD lesion. In the present study, histological examination and clinical outcome revealed a diagnosis of MTX-associated LPD, which is a form of immunosuppression-related LPD. As in the present case, about 40% of LPD in RA patients treated with MTX are EBV-positive [6, 11]. Latent EBV infection may be involved in the development of EBV-associated B-cell LPDs, like those occurring in immunosuppressed patients [21]. It is hypothesized that the withdrawal of MTX results in partial recovery of the immune system, with subsequent elimination of the malignant clone due to enhanced oncogenic surveillance [22]. Although EBV-positive LPDs or lymphomas have a special tendency to undergo spontaneous remission after MTX is withdrawn [6, 7], it was striking that even such an extensive and destructive lesion, as in the present case, completely regressed within 3 weeks after MTX was simply withdrawn. Steroidal or nonsteroidal anti-inflammatory drug use is unlikely to have been responsible for the disease remission seen in our patient [23]. On the other hand, EBV-associated lymphoma can sometimes be lethal [24]. Hence, pathological examination was deemed to be important in the present case. If no remission was seen within 3 weeks of MTX withdrawal, the therapeutic plan was to immediately treat

the condition as a diffuse large B-cell lymphoma (DLBCL); most cases of these are non-Hodgkin's B-cell lymphomas of the large cell or diffuse mixed type [25], although he did not perfectly fulfill the pathological criteria for DLBCL.

Physicians should be aware of the adverse effects of MTX therapy and the possible value of MTX cessation with subsequent close monitoring for regression prior to considering radiotherapy or chemotherapy in patients receiving MTX therapy, even if the lesions look like destructive lymphomas. Further, since some patients with initial regression of LPD after cessation of MTX experience a recurrence of LPD at a later date [26], patients with MTX-associated LPD should continue to be monitored for a while, even after complete recovery from the disease.

In conclusion, patients in whom MTX-associated lymphomas or LPDs are suspected should be initially managed by withdrawal of MTX. If no regression is seen within 3 weeks after MTX cessation, chemotherapy and/or radiation therapy should be considered as soon as possible in order to avoid disease progression. Histological diagnosis and close monitoring for regression after MTX cessation are important in these patients.

Acknowledgments. This work was supported by grants from the Ministry of Education, Culture, Sports, Science and Technology, Japan (no. 25462684 to Y.O.).

References

1. Deeming GMJ, Collingwood J and Pemberton MN: Methotrexate and oral ulceration. *Br Dent J* (2005) 198: 83–85.
2. Mielants H, Veys EM, Van der Straeten C, Ackerman C and Goemaere S: The efficacy and toxicity of a constant low dose of methotrexate as a treatment for intractable rheumatoid arthritis: an open prospective study. *J Rheumatol* (1991) 18: 978–983.
3. McKendry RJ and Dale P: Adverse effects of low dose methotrexate therapy in rheumatoid arthritis. *J Rheumatol* (1993) 20: 1850–1856.
4. Salaffi F, Carotti M, Sartini A and Cervini C: A prospective study of the long-term efficacy and toxicity of low-dose methotrexate in rheumatoid arthritis. *Clin Exp Rheumatol* (1995) 13: 23–28.
5. Schnabel A and Gross WL: Low-dose methotrexate in rheumatic diseases—efficacy, side effects, and risk factors for side effects. *Semin Arthritis Rheum* (1994) 23: 310–327.
6. Gaulard P, Swerdlow SH, Harris NL, Jaffe ES and Sundstrom C: Other iatrogenic immunodeficiency associated lymphoproliferative disorders; in *WHO classification of tumors of the haematopoietic and lymphoid tissues*, Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J and Vardiman JW eds, 4th Ed, International Agency for Research on Cancer, Lyon (2008) pp 350–

- 351.
7. Miyazaki T, Fujimaki K, Shirasugi Y, Yoshida F, Ohsaka M, Miyazaki K, Yamazaki E, Sakai R, Tamaru J, Kishi K, Kanamori H, Higashihara M, Hotta T and Ishigatsubo Y: Remission of lymphoma after withdrawal of methotrexate in rheumatoid arthritis: relationship with type of latent Epstein-Barr virus infection. *Am J Hematol* (2007) 82: 1106–1109.
 8. de Mast Q, Haverman J, Netten PM and Sinnige HA: Remission of a primary thyroid lymphoma after methotrexate withdrawal. *Clin Endocrinol (Oxf)* (2006) 64: 716–717.
 9. Gono T, Shimojima Y, Hoshi K, Yamamoto K, Tokuda T, Shikama N, Matsuda M and Ikeda S: Malignant lymphoma associated with rheumatoid arthritis, developing shortly after initiation of oral methotrexate. *Intern Med* (2004) 43: 135–138.
 10. Olsen EA: The pharmacology of methotrexate. *J Am Acad Dermatol* (1991) 25: 306–318.
 11. Kalantzi A, Marshman Z, Falconer DT, Morgan PR and Odell EW: Oral effects of low-dose methotrexate treatment. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* (2005) 100: 52–62.
 12. British National Formulary, Dinesh K. Mehta ed, vol. 45, British Medical Association and Royal Pharmaceutical Society of Great Britain, London (2003).
 13. Bookstaver PB, Norris L, Rudisill C, DeWitt T, Aziz S and Fant J: Multiple toxic effects of low-dose methotrexate in a patient treated for psoriasis. *Am J Health Syst Pharm* (2008) 65: 2117–2121.
 14. Getov I, Dimitrova Z and Petkova V: Low dose treatment with methotrexate-adverse drug reactions survey. *Boll Chim Farm* (2000) 139: 153–158.
 15. Ortiz Z, Shea B, Suarez-Almazor M, Moher D, Wells GA and Tugwell P: The efficacy of folic acid and folic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis. A metaanalysis of randomized controlled trials. *J Rheumatol* (1998) 25: 36–43.
 16. Kean WF and Kean IR: Clinical pharmacology of gold. *Inflammopharmacology* (2008) 16: 112–125.
 17. Salloum E, Cooper DL, Howe G, Lacy J, Tallini G, Crouch J, Schultz M and Murren J: Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases. *J Clin Oncol* (1996) 14: 1943–1949.
 18. Wolfe F and Michaud K: Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18572 patients. *Arthritis Rheum* (2004) 50: 1740–1751.
 19. Mariette X, Cazals-Hatem D, Warszawski J, Liote F, Balandraud N and Sibilia J; Investigators of the Club Rhumatismes et Inflammation: Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. *Blood* (2002) 99: 3909–3915.
 20. Hoshida Y, Xu JX, Fujita S, Nakamichi I, Ikeda J, Tomita Y, Nakatsuka S, Tamaru J, Iizuka A, Takeuchi T and Aozasa K: Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication. *J Rheumatol* (2007) 34: 322–331.
 21. Loren AW, Porter DL, Stadtmauer EA and Tsai DE: Post-transplant lymphoproliferative disorder: a review. *Bone Marrow Transplant* (2003) 31: 145–155.
 22. Georgescu L and Paget SA: Lymphoma in patients with rheumatoid arthritis: what is the evidence of a link with methotrexate? *Drug Saf* (1999) 20: 475–487.
 23. Thonhofer R, Gaugg M, Kriessmayr M, Neumann HJ and Erlacher L: Spontaneous remission of marginal zone B cell lymphoma in a patient with seropositive rheumatoid arthritis after discontinuation of infliximab-methotrexate treatment. *Ann Rheum Dis* (2005) 64: 1098–1099.
 24. Hsiao SC, Ichinohasama R, Lin SH, Liao YL, Chang ST, Cho CY and Chuang SS: EBV-associated diffuse large B-cell lymphoma in a psoriatic treated with methotrexate. *Pathol Res Pract* (2009) 205: 43–49.
 25. Soubrier M, Arrestier S, Bouloudian S, Dubost JJ and Ristori JM: Epstein-Barr virus infection associated hepatic lymphoma in a patient treated with methotrexate for rheumatoid arthritis. *Joint Bone Spine* (2006) 73: 218–219.
 26. Hatanaka K, Nakamura N, Kojima M, Ando K, Irie S, Bunno M, Nakamine H and Uekusa T: Methotrexate-associated lymphoproliferative disorders mimicking angioimmunoblastic T-cell lymphoma. *Pathol Res Pract* (2010) 206: 9–13.